BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32591641)

  • 1. Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.
    Duque-Afonso J; Ihorst G; Waterhouse M; Zeiser R; Wäsch R; Bertz H; Yücel M; Köhler T; Müller-Quernheim J; Marks R; Finke J
    Bone Marrow Transplant; 2021 Jan; 56(1):110-120. PubMed ID: 32591641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
    Duque-Afonso J; Finke J; Ngoya M; Galimard JE; Craddock C; Raj K; Bloor A; Nicholson E; Eder M; Kim O; Valerius T; Snowden JA; Tholouli E; Crawley C; Collin M; Wilson KMO; Gadisseur A; Protheroe R; Wagner-Drouet EM; Savani BN; Spyridonidis A; Ciceri F; Nagler A; Mohty M
    Bone Marrow Transplant; 2024 Feb; 59(2):247-254. PubMed ID: 38040842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
    Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
    Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.
    Marks R; Potthoff K; Hahn J; Ihorst G; Bertz H; Spyridonidis A; Holler E; Finke JM
    Blood; 2008 Jul; 112(2):415-25. PubMed ID: 18451310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
    Wäsch R; Reisser S; Hahn J; Bertz H; Engelhardt M; Kunzmann R; Veelken H; Holler E; Finke J
    Bone Marrow Transplant; 2000 Aug; 26(3):243-50. PubMed ID: 10967561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
    Wais V; Kündgen L; Bohl SR; von Harsdorf S; Schlenk RF; Döhner K; Teleanu V; Bullinger L; Nguyen TM; Drognitz K; Moulin JC; Binnenhei M; Bentz M; Döhner H; Bunjes D; Kuchenbauer F; Ringhoffer M
    Bone Marrow Transplant; 2018 Jan; 53(1):94-96. PubMed ID: 29131153
    [No Abstract]   [Full Text] [Related]  

  • 8. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
    Bashir Q; Khan H; Thall PF; Liu P; Shah N; Kebriaei P; Parmar S; Oran B; Ciurea S; Nieto Y; Jones R; Hosing CM; Popat UR; Dinh YT; Rondon G; Orlowski RZ; Shah JJ; De Lima M; Shpall E; Champlin R; Giralt S; Qazilbash MH
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1453-8. PubMed ID: 23872222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine/Melphalan 100 mg/m
    Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation.
    Duque-Afonso J; Ihorst G; Wäsch R; Bertz H; Müller-Quernheim J; Finke J; Prasse A; Marks R
    Bone Marrow Transplant; 2013 Aug; 48(8):1098-103. PubMed ID: 23376822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
    Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
    Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
    Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
    Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma.
    Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):655-63. PubMed ID: 26428486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
    Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning.
    Gherman RF; Ewald S; Ihorst G; Strüßmann T; Zeiser R; Wäsch R; Bertz H; Stolz D; Duyster J; Finke J; Marks R; Engelhardt M; Duque-Afonso J
    Eur J Haematol; 2024 Mar; 112(3):350-359. PubMed ID: 37823328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
    Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):53-59. PubMed ID: 27771496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
    Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
    Jain T; Kunze KL; Temkit M; Partain DK; Patnaik MS; Slack JL; Khera N; Hogan WJ; Roy V; Noel P; Leis JF; Sproat LZ; Fauble V; Mesa RA; Palmer J
    Bone Marrow Transplant; 2019 Feb; 54(2):204-211. PubMed ID: 29795431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.